

October 2021

medical benefit specialty drug update **bulletin**

Specialty Drug Program Updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage, and Value & Balance Exchange

Review the following table to determine changes to our specialty medical injectable drug programs.

UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	UHC Value & Balance Exchange	Treatment Uses	Summary of Changes
Nexvazyme® (avalglucosidase alfa-ngpt)	1/1/2022	X			X	Indicated to treat patients 1 year of age and older with late-onset Pompe disease to help reduce glycogen accumulation in muscle cells.	<ul style="list-style-type: none"> Add notification/prior authorization. For Commercial, add Site of Care.
Nulibry™ (fosdenopterin)	1/1/2022		X			Reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.	<ul style="list-style-type: none"> Add notification/prior authorization.
Ryplazim® (plasminogen, human tvmh)	1/1/2022	X	X	X	X	Indicated to treat plasminogen deficiency type 1 (hypoplasminogenemia).	<ul style="list-style-type: none"> Add notification/prior authorization. For Commercial, add Site of Care.
Saphnelo™ (anifrolumab-fnia)	1/1/2022	X	X	X	X	Indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE).	<ul style="list-style-type: none"> Add notification/prior authorization. For Commercial, add Site of Care.

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member's eligibility changes. You don't need to submit a new notification/prior authorization request for members who already have authorization for these medications on the effective date noted above.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 -RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. This exception does not apply to Medicaid and Medicare.



New and Updated Procedure Codes for Injectable Medications – Effective October 1st, 2021

Effective October 1, 2021, new procedure codes were created for certain drugs due to updates from the Centers for Medicare & Medicaid Services (CMS). Correct coding rules dictate that assigned and permanent codes should be used when available. The following injectable medications will have new codes:

- Amondys-45 (casimersen) (J1426)
- Breyanzi (lisocabtagene maraleucel) (Q2054)
- Cabenuva (cabotegravir and rilpivirine) (J0741)
- Evkeeza (evinacumab-dgnb) (J1305)
- Abecma (idecabtagene vicleucel) (C9081)